Soluble E-cadherin Fragments in Cancer Patients
Author Information
Author(s): M. Katayama, S. Hirai, K. Kamihagi, K. Nakagawa, M. Yasumoto, I. Kato
Primary Institution: Biotechnology Research Laboratories, Takara Shuzo Co., Ltd
Hypothesis
Can soluble E-cadherin levels in serum be used as a tumor marker for cancer patients?
Conclusion
Soluble E-cadherin levels are significantly elevated in cancer patients compared to healthy individuals, indicating its potential as a tumor marker.
Supporting Evidence
- Serum E-cadherin levels in cancer patients were significantly higher than in healthy subjects.
- 53.7% of cancer patients exhibited elevated soluble E-cadherin levels.
- Patients with gastric cancer had an average E-cadherin level of 3.51 µg/ml.
- Patients with hepatocellular cancer had an average E-cadherin level of 5.55 µg/ml.
- Diabetic patients did not show elevated E-cadherin levels compared to healthy subjects.
Takeaway
Doctors found that a special protein called E-cadherin is higher in the blood of cancer patients, which might help them check for cancer.
Methodology
Monoclonal antibodies were used in an immunoenzymometric assay to measure soluble E-cadherin levels in serum samples from cancer patients and healthy individuals.
Limitations
The study did not include patients who had received prior chemotherapy or radiotherapy.
Participant Demographics
The study included 140 individuals: 56 healthy subjects, 26 diabetic patients, 4 patients with acute hepatitis, and 54 cancer patients.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website